Voyager Therapeutics Stock Buy Hold or Sell Recommendation
| VYGR Stock | USD 4.42 0.01 0.23% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Voyager Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Voyager Therapeutics within the specified time frame.Check out Voyager Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide. Note, we conduct extensive research on individual companies such as Voyager and provide practical buy, sell, or hold advice based on investors' constraints. Voyager Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
Execute Voyager Therapeutics Buy or Sell Advice
The Voyager recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Voyager Therapeutics. Macroaxis does not own or have any residual interests in Voyager Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Voyager Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Soft | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Small | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Voyager Therapeutics Trading Alerts and Improvement Suggestions
| Voyager Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 80 M. Net Loss for the year was (65 M) with loss before overhead, payroll, taxes, and interest of (102.99 M). | |
| Voyager Therapeutics currently holds about 148.06 M in cash with (15.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.83. | |
| Roughly 55.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from insidermonkey.com: Voyager Therapeutics Strong Q3 Prompts Bullish Coverage |
Voyager Therapeutics Returns Distribution Density
The distribution of Voyager Therapeutics' historical returns is an attempt to chart the uncertainty of Voyager Therapeutics' future price movements. The chart of the probability distribution of Voyager Therapeutics daily returns describes the distribution of returns around its average expected value. We use Voyager Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Voyager Therapeutics returns is essential to provide solid investment advice for Voyager Therapeutics.
| Mean Return | 0.17 | Value At Risk | -4.9 | Potential Upside | 6.22 | Standard Deviation | 4.03 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Voyager Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Voyager Stock Institutional Investors
The Voyager Therapeutics' institutional investors refer to entities that pool money to purchase Voyager Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | T. Rowe Price Associates, Inc. | 2025-06-30 | 610.9 K | Bank Of America Corp | 2025-06-30 | 576.5 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 563.4 K | Ubs Group Ag | 2025-06-30 | 455.5 K | Northern Trust Corp | 2025-06-30 | 404.5 K | Renaissance Technologies Corp | 2025-06-30 | 392.1 K | Royal Bank Of Canada | 2025-06-30 | 290.1 K | Aqr Capital Management Llc | 2025-06-30 | 283.2 K | Goldman Sachs Group Inc | 2025-06-30 | 280.9 K | Blackrock Inc | 2025-06-30 | 5.7 M | Armistice Capital, Llc | 2025-06-30 | 4.8 M |
Voyager Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 18.4M | 13.0M | (18.5M) | (30.1M) | 3.8M | 4.9M | |
| Free Cash Flow | (108.8M) | (55.1M) | (15M) | 74.7M | (18.8M) | (19.8M) | |
| Other Non Cash Items | 7.3M | 9.2M | 7.2M | (3.4M) | (4.7M) | (4.4M) | |
| Capital Expenditures | 12.1M | 1.6M | 2.5M | 3.3M | 3.5M | 4.4M | |
| Net Income | 36.7M | (71.2M) | (46.4M) | 132.3M | (65.0M) | (61.8M) | |
| End Period Cash Flow | 104.4M | 117.4M | 99.0M | 70.4M | 74.2M | 64.8M | |
| Investments | 125.1M | 67.5M | (4.8M) | (141.6M) | (94.9M) | (90.1M) | |
| Depreciation | 3.8M | 5.2M | 6.2M | 4.4M | 4.7M | 3.2M | |
| Change To Netincome | 14.0M | 14.9M | 11.3M | 9.7M | 11.2M | 12.7M |
Voyager Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Voyager Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Voyager Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Voyager stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.01 | |
β | Beta against Dow Jones | 1.52 | |
σ | Overall volatility | 4.03 | |
Ir | Information ratio | 0.02 |
Voyager Therapeutics Volatility Alert
Voyager Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Voyager Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Voyager Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Voyager Therapeutics Fundamentals Vs Peers
Comparing Voyager Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Voyager Therapeutics' direct or indirect competition across all of the common fundamentals between Voyager Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Voyager Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Voyager Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Voyager Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Voyager Therapeutics to competition |
| Fundamentals | Voyager Therapeutics | Peer Average |
| Return On Equity | -0.46 | -0.31 |
| Return On Asset | -0.25 | -0.14 |
| Operating Margin | (2.29) % | (5.51) % |
| Current Valuation | 231.7 M | 16.62 B |
| Shares Outstanding | 55.6 M | 571.82 M |
| Shares Owned By Insiders | 16.14 % | 10.09 % |
| Shares Owned By Institutions | 55.10 % | 39.21 % |
| Number Of Shares Shorted | 3.33 M | 4.71 M |
| Price To Earning | 5.62 X | 28.72 X |
| Price To Book | 1.09 X | 9.51 X |
| Price To Sales | 7.85 X | 11.42 X |
| Revenue | 80 M | 9.43 B |
| Gross Profit | (102.99 M) | 27.38 B |
| EBITDA | (78.56 M) | 3.9 B |
| Net Income | (65 M) | 570.98 M |
| Cash And Equivalents | 148.06 M | 2.7 B |
| Cash Per Share | 3.83 X | 5.01 X |
| Total Debt | 43.73 M | 5.32 B |
| Debt To Equity | 0.40 % | 48.70 % |
| Current Ratio | 1.55 X | 2.16 X |
| Book Value Per Share | 3.96 X | 1.93 K |
| Cash Flow From Operations | (15.31 M) | 971.22 M |
| Short Ratio | 7.07 X | 4.00 X |
| Earnings Per Share | (2.17) X | 3.12 X |
| Target Price | 15.0 | |
| Number Of Employees | 172 | 18.84 K |
| Beta | 1.24 | -0.15 |
| Market Capitalization | 245.75 M | 19.03 B |
| Total Asset | 393.05 M | 29.47 B |
| Retained Earnings | (326.18 M) | 9.33 B |
| Working Capital | 227.02 M | 1.48 B |
| Current Asset | 195.89 M | 9.34 B |
| Current Liabilities | 23.93 M | 7.9 B |
Note: Disposition of 10885 shares by Sandrock Alfred of Voyager Therapeutics at 3.43 subject to Rule 16b-3 [view details]
Voyager Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Voyager . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Voyager Therapeutics Buy or Sell Advice
When is the right time to buy or sell Voyager Therapeutics? Buying financial instruments such as Voyager Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Voyager Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Soft Drinks Thematic Idea Now
Soft Drinks
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 6 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.